Do vaccinated cases transmit measles? A systematic review and meta-analysis.

Expert Rev VaccinesAug 14, 2026 (epub)
Clinical ResearchInfectious DiseasesPreventive Medicine / Public Health

James Wright, Natasha S Crowcroft, Julie Perry et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined measles transmission from vaccinated individuals, analyzing data from 33 studies. It found that 70 vaccinated individuals transmitted the virus, resulting in 237 secondary cases. The analysis highlights that while such transmissions are uncommon, they can still contribute to outbreaks, necessitating consideration in public health strategies.

Key findings

  • Seventy vaccinated individuals transmitted measles, leading to 237 secondary cases.
  • Vaccinated transmitters in eliminated areas had a median age of 19 years, compared to 16 years in non-eliminated areas.
  • A total of 812 measles cases were traced back to vaccinated individuals, with a median of 4 cases per vaccinated transmitter.

Why it matters

Understanding the potential for measles transmission from vaccinated individuals is crucial for public health planning and outbreak management. This knowledge can inform vaccination strategies and response efforts during measles outbreaks.

Source

PubMed · PMID 42599107

Published in Expert Rev Vaccines. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.